论文部分内容阅读
肝细胞肝癌(hepatocellular carcinoma,HCC)是人类常见的恶性肿瘤,在所有恶性肿瘤中其死亡率位居第3位。目前,索拉非尼是晚期HCC唯一批准上市的分子靶向治疗药物。然而,索拉非尼在晚期HCC中的治疗效果并不理想,存在较大的个体差异。为了优化晚期HCC患者的治疗方案,减少医疗支出,改善患者的生活质量,人们对预测索拉非尼治疗晚期HCC疗效生物标志物的研究越来越重视。研究表明,肿瘤组织中磷酸化细胞外调节蛋白激酶(phosphorylated extracellular signal regulated kinase,p ERK)、c-Jun氨基末端激酶(c-Jun N-terminal kinase,JNK)信号通路下游的c-Jun磷酸化水平和血管内皮生长因子受体2(vascular endothelial growth factor receptor-2,VEGFR-2)的表达水平,血清中甲胎蛋白(alpha-fetoprotein,AFP)、转化生长因子(transforming growth factor,TGF)和血管内皮生长因子(vascular endothelial growth factor,VEGF)的浓度,以及循环肿瘤细胞中p ERK和磷酸化蛋白激酶B(protein kinase B,PKB,又称Akt)的表达,是预测索拉非尼疗效的重要因素,具有作为新的生物标志物的应用前景。本文对近年来的相关临床队列研究进行综述。
Hepatocellular carcinoma (HCC) is a common human malignancy, with the highest mortality rate in all malignancies. Currently, sorafenib is the only molecular targeted drug approved for advanced HCC. However, the efficacy of sorafenib in the treatment of advanced HCC is not satisfactory, with large individual differences. In order to optimize the treatment of advanced HCC patients, reduce medical expenses and improve the quality of life of patients, people pay more and more attention to predict the efficacy of sorafenib in the treatment of advanced HCC. Studies have shown that c-Jun phosphorylation downstream of phosphorylated extracellular signal regulated kinase (p ERK) and c-Jun N-terminal kinase (JNK) signaling pathways in tumor tissue And the level of vascular endothelial growth factor receptor-2 (VEGFR-2), the level of serum alpha-fetoprotein (AFP), transforming growth factor (TGF) The concentration of vascular endothelial growth factor (VEGF) and the expression of p ERK and phosphorylated protein kinase B (PKB) in circulating tumor cells are predictive of the efficacy of sorafenib Important factors, with the application prospect as a new biomarker. This article reviews recent clinical cohort studies.